Literature DB >> 11720438

p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.

M A Le Frère-Belda1, D Cappellen, A Daher, S Gil-Diez-de-Medina, F Besse, C C Abbou, J P Thiery, E S Zafrani, D K Chopin, F Radvanyi.   

Abstract

The p15 gene which encodes a cyclin-dependent kinase inhibitor, is located in the 9p21 chromosomal region that is frequently deleted in human bladder transitional cell carcinomas (TCCs). The aim of the present paper is to study the potential involvement of the p15 gene in the evolution of TCCs. p15 mRNA expression was investigated by semi-quantitative RT-PCR in a series of 75 TCCs, 13 bladder cell lines and 6 normal bladder urothelia by semi-quantitative RT-PCR. p15 was expressed in the normal urothelium but p15 mRNA levels were significantly decreased in 66% of the superficial (Ta-T1) TCCs (P = 0.0015). In contrast, in muscle-invasive (T2-T4) TCCs, p15 expression differed widely between samples. p16 mRNA levels were also studied and there was no correlation between p15 and p16 mRNA levels, thus indicating that the two genes were regulated independently. Lower p15 expression in superficial tumours did not reflect a switch from quiescence to proliferative activity as normal proliferative urothelial controls did not present decreased p15 mRNA levels relative to quiescent normal urothelia. We further investigated the mechanisms underlying p15 down regulation. Homozygous deletions of the p15 gene, also involving the contiguous p16 gene, were observed in 42% of the TCCs with decreased p15 expression. No hypermethylation at multiple methylation-sensitive restriction sites in the 5;-CpG island of p15 was encountered in the remaining tumours. Our data suggest that decreased expression of p15 may be an important step in early neoplastic transformation of the urothelium and that a mechanism other than homozygous deletions or hypermethylation, may be involved in p15 down regulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720438      PMCID: PMC2363957          DOI: 10.1054/bjoc.2001.2106

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

Review 1.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.

Authors:  M Hall; G Peters
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

2.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

Authors:  M Gonzalez-Zulueta; C M Bender; A S Yang; T Nguyen; R W Beart; J M Van Tornout; P A Jones
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

3.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

4.  Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.

Authors:  J P Packenham; J A Taylor; C H Anna; C M White; T R Devereux
Journal:  Mol Carcinog       Date:  1995-11       Impact factor: 4.784

5.  p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.

Authors:  M P Williamson; P A Elder; M E Shaw; J Devlin; M A Knowles
Journal:  Hum Mol Genet       Date:  1995-09       Impact factor: 6.150

6.  5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

Authors:  A Merlo; J G Herman; L Mao; D J Lee; E Gabrielson; P C Burger; S B Baylin; D Sidransky
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 7.  Cell-cycle regulators and cancer.

Authors:  A Kamb
Journal:  Trends Genet       Date:  1995-04       Impact factor: 11.639

8.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.

Authors:  J G Herman; J Jen; A Merlo; S B Baylin
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

9.  Genomic structure, expression and mutational analysis of the P15 (MTS2) gene.

Authors:  S Stone; P Dayananth; P Jiang; J M Weaver-Feldhaus; S V Tavtigian; L Cannon-Albright; A Kamb
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

10.  Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.

Authors:  J Southgate; J Proffitt; P Roberts; B Smith; P Selby
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more
  4 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

3.  Promoter hypermethylation of tumor suppressor genes correlates with tumor grade and invasiveness in patients with urothelial bladder cancer.

Authors:  Shumaila M Bilgrami; Sohail A Qureshi; Shahid Pervez; Farhat Abbas
Journal:  Springerplus       Date:  2014-04-05

4.  Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors.

Authors:  Michèle J Hoffmann; Judith Dehn; Johanna Droop; Günter Niegisch; Christian Niedworok; Tibor Szarvas; Wolfgang A Schulz
Journal:  Noncoding RNA       Date:  2015-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.